Abiopharma

Vericel Corporation (VCEL) Reports the reporting period Financial Results Vericel Corporation (VCEL) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: $276 Million
• Net Income: $200 million
• EPS: Not disclosed
• Cash and equivalents: Not disclosed
  • Highest number of MACI implants, implanting surgeons, surgeons taking biopsies and MACI biopsies in any quarter since launch in the fourth quarter
  • MACI revenue growth of 20% or more for the third consecutive year
  • Completed MACI sales force expansion